Part of the HELP.CH ® Network
Swiss News Now is a news platform with the latest news and information from Swiss companies and Swiss authorities. Latest news from Switzerland in English.
London – The global economy is expected to strengthen in 2027, but growth increasingly depends on a relatively small number of sectors and sources of demand: AI investment, strong financial markets, spending by wealthier households and strategic investments in infrastructure and defence. The key question is whether AI investment will deliver broader productivity and income gains across the wider economy before rising borrowing costs put more pressure on businesses, according to Swiss Re Institute's latest sigma "Searching for resilience – Global Economic and Insurance Market Outlook 2027–2028".
Why have small boat crossings to the UK risen and fallen, who's making the journey and why are the crossings so difficult to stop?
Deloitte Switzerland generated net revenue of CHF 562.5 million in the 2025/26 financial year (-3.9 per cent). Geopolitical, economic and legal uncertainties put the brakes on investment by many companies, which had a particularly strong impact on the advisory business. The Tax & Legal business line experienced growth, while Audit & Assurance remained at the previous year’s level. Deloitte kept up its investments in its employees, AI and society at large, and also hired 450 new employees in the reporting year, including many young university graduates.
Zug, Switzerland – Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expands its availability for chin augmentation, where it is already approved across various markets globally including Europe, Brazil, Canada and Thailand. Restylane Shaype has been purposefully developed as a firmer gel to deliver a unique bone-mimicking effect and enable natural-looking structural enhancement without surgery.
The ninth China International Import Expo (CIIE) has successfully drawn to a close, marking the resounding culmination of Richemont’s seventh consecutive participation in the event. The occasion held particular significance as the Group marked the twentieth anniversary of its presence in China. Under the theme “Crafting Bonds: The Art of Human Connection”, Richemont brought together five of its Maisons in a carefully curated presentation of time-honoured masterpieces and new creations, revealing the enduring craftsmanship and human stories behind each work.
Rothschild & Co is pleased to announce that it has appointed Geoffroy de Ridder as Group Chief Technology and Operations Officer (CTOO) and CTOO for its Wealth and Asset Management business, effective December 2026.
Bookings rose by 34.4% to CHF 201.7 million (H1 2025/26: CHF 150.1 million), driven primarily by Automation, Renewable Energy and Energy Distribution & High Precision. The book-to-bill ratio reached 1.16, pointing to a gradual recovery in demand.
Composable platform enables wealth managers to connect fragmented investment data, scale personalized portfolio management and add capabilities without replacing their existing technology stack.
Zug, Switzerland – The Board of COFRA Holding AG (“COFRA”) announces the appointment of Georg Wunderlin as Chief Executive Officer (CEO) and a member of the COFRA Board of Directors, effective in April 2027.
Swiss Re reported a net income of USD 1.3 billion for the third quarter of 2026, resulting in a net income of USD 4.2 billion and a return on equity (ROE) of 22.5% for the first nine months of the year. The Group's financial performance benefited from strong contributions from all Business Units, supported by lower-than-expected natural catastrophe losses and a solid investment result. The Group and all Business Units are well on track towards their 2026 financial targets.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. -- Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of new preclinical data supporting an attractive therapeutic window for MP0632, a logic-gated Switch-DARPin T cell engager (TCE) with integrated CD2 co-stimulation, at the Society for Immunotherapy of Cancer (SITC) 2026 conference.
SwissNewsNow.com is a news platform focused on current developments from Switzerland and part of the
HELP.CH ® network.
The platform provides readers with a compact overview of Swiss news, business developments, company information, innovation, technology and society. Selected content is sourced from the HELP.CH news network and related media platforms.
SwissNewsNow.com helps make important Swiss news accessible through structured publication, search engine visibility and distribution across digital channels.
More about the network:
help.swiss/en
The network includes news platforms such as Aktuellenews.ch, HELP.CH News, Swiss-Press.com, Tagesthemen.ch, Aktuellenews.de and Aktuellenews.at. Together they provide coverage of Swiss business, technology, innovation, society and economic developments.
SwissNewsNow.com brings together selected news and information from across the network, providing readers with a convenient gateway to relevant Swiss topics and current developments.